Metabolic dysfunction-associated steatohepatitis (MASH) significantly increases the risk of liver cirrhosis and ...

Emerging evidence suggests that fibroblast growth factor 21 (FGF21) could play a future part in the treatment of metabolic ...

A 96-week clinical trial found that 300 mg of Vitamin E significantly improved liver histology and reduced inflammation in ...

Nonalcoholic steatohepatitis (NASH) is the progressive form of liver injury that carries a risk for progressive fibrosis, cirrhosis, and end-stage liver disease. Hepatocellular carcinoma (HCC ...

Steatohepatitis is an advanced stage liver dysfunction associated with steatotic liver disease. In an interview with HT lifestyle, Dr. Rohit Mehtani, assistant professor, Department of Hepatology ...

Altimmune's existence depends almost entirely on the outcome of the Phase 2 trial for pemvidutide in MASH. Learn why ALT ...

Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on ...

Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that ...

Additional analysis of data from the NAVIGATE trial showed statistically significant 68.1% (p=0.02) reduction in the incidence of new varices ...